135 related articles for article (PubMed ID: 19741564)
1. Effect of DNA repair host factors on temozolomide or dacarbazine melanoma treatment in Caucasians.
Boeckmann L; Schirmer M; Rosenberger A; Struever D; Thoms KM; Gutzmer R; Has C; Kunz M; Kuschal C; Laspe P; Schoen MP; Brockmoeller J; Emmert S
Pharmacogenet Genomics; 2009 Oct; 19(10):760-9. PubMed ID: 19741564
[TBL] [Abstract][Full Text] [Related]
2. Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O⁶-methylguanine-DNA methyltransferase and mismatch repair proteins.
Querfeld C; Rosen ST; Guitart J; Rademaker A; Pezen DS; Dolan ME; Baron J; Yarosh DB; Foss F; Kuzel TM
Clin Cancer Res; 2011 Sep; 17(17):5748-54. PubMed ID: 21747120
[TBL] [Abstract][Full Text] [Related]
3. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.
Felsberg J; Thon N; Eigenbrod S; Hentschel B; Sabel MC; Westphal M; Schackert G; Kreth FW; Pietsch T; Löffler M; Weller M; Reifenberger G; Tonn JC;
Int J Cancer; 2011 Aug; 129(3):659-70. PubMed ID: 21425258
[TBL] [Abstract][Full Text] [Related]
4. Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours.
von Bueren AO; Bacolod MD; Hagel C; Heinimann K; Fedier A; Kordes U; Pietsch T; Koster J; Grotzer MA; Friedman HS; Marra G; Kool M; Rutkowski S
Br J Cancer; 2012 Oct; 107(8):1399-408. PubMed ID: 22976800
[TBL] [Abstract][Full Text] [Related]
5. Effects of temozolomide (TMZ) on the expression and interaction of heat shock proteins (HSPs) and DNA repair proteins in human malignant glioma cells.
Castro GN; Cayado-Gutiérrez N; Zoppino FC; Fanelli MA; Cuello-Carrión FD; Sottile M; Nadin SB; Ciocca DR
Cell Stress Chaperones; 2015 Mar; 20(2):253-65. PubMed ID: 25155585
[TBL] [Abstract][Full Text] [Related]
6. MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma.
Tuominen R; Jewell R; van den Oord JJ; Wolter P; Stierner U; Lindholm C; Hertzman Johansson C; Lindén D; Johansson H; Frostvik Stolt M; Walker C; Snowden H; Newton-Bishop J; Hansson J; Egyházi Brage S
Int J Cancer; 2015 Jun; 136(12):2844-53. PubMed ID: 25400033
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution.
Boeckmann L; Nickel AC; Kuschal C; Schaefer A; Thoms KM; Schön MP; Thomale J; Emmert S
Melanoma Res; 2011 Jun; 21(3):206-16. PubMed ID: 21460749
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.
Norden AD; Lesser GJ; Drappatz J; Ligon KL; Hammond SN; Lee EQ; Reardon DR; Fadul CE; Plotkin SR; Batchelor TT; Zhu JJ; Beroukhim R; Muzikansky A; Doherty L; Lafrankie D; Smith K; Tafoya V; Lis R; Stack EC; Rosenfeld MR; Wen PY
Neuro Oncol; 2013 Jul; 15(7):930-5. PubMed ID: 23553268
[TBL] [Abstract][Full Text] [Related]
9. Modulation of the efficacy of temozolomide and dacarbazine melanoma treatment by DNA-repair factors in vivo and in vitro.
Boeckmann L; Thoms KM; Gutzmer R; Has C; Kunz M; Kuschal C; Laspe P; Struever D; Emmert S
Int J Clin Pharmacol Ther; 2009 Jan; 47(1):33-5. PubMed ID: 19203531
[No Abstract] [Full Text] [Related]
10. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models.
Middlemas DS; Stewart CF; Kirstein MN; Poquette C; Friedman HS; Houghton PJ; Brent TP
Clin Cancer Res; 2000 Mar; 6(3):998-1007. PubMed ID: 10741727
[TBL] [Abstract][Full Text] [Related]
11. O6-methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor induced resistance against temozolomide in human melanoma cells.
Fontijn D; Adema AD; Bhakat KK; Pinedo HM; Peters GJ; Boven E
Mol Cancer Ther; 2007 Oct; 6(10):2807-15. PubMed ID: 17938272
[TBL] [Abstract][Full Text] [Related]
12. A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system.
Alvino E; Castiglia D; Caporali S; Pepponi R; Caporaso P; Lacal PM; Marra G; Fischer F; Zambruno G; Bonmassar E; Jiricny J; D'Atri S
Int J Oncol; 2006 Oct; 29(4):785-97. PubMed ID: 16964376
[TBL] [Abstract][Full Text] [Related]
13. Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma.
Ganesa S; Sule A; Sundaram RK; Bindra RS
Sci Rep; 2022 Apr; 12(1):5827. PubMed ID: 35388070
[TBL] [Abstract][Full Text] [Related]
14. [Cellular markers based on DNA damage and repair (BER, MMR), expression of MLHI, MSH2, FasR, and cell death of lymphocytes as predictive parameters for clinical response to chemotherapy of melanoma].
Tronov VA; Artamonov DN; Abramov ME; Gorbacheva LB
Tsitologiia; 2011; 53(1):10-6. PubMed ID: 21473113
[TBL] [Abstract][Full Text] [Related]
15. Analysis of O(6)-methylguanine-DNA methyltransferase in melanoma tumours in patients treated with dacarbazine-based chemotherapy.
Ma S; Egyházi S; Martenhed G; Ringborg U; Hansson J
Melanoma Res; 2002 Aug; 12(4):335-42. PubMed ID: 12170182
[TBL] [Abstract][Full Text] [Related]
16. Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma.
Shinsato Y; Furukawa T; Yunoue S; Yonezawa H; Minami K; Nishizawa Y; Ikeda R; Kawahara K; Yamamoto M; Hirano H; Tokimura H; Arita K
Oncotarget; 2013 Dec; 4(12):2261-70. PubMed ID: 24259277
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of DNA mismatch repair protein and O6-methylguanine-DNA methyltransferase in melanoma metastases in relation to clinical response to DTIC-based chemotherapy.
Ma S; Egyházi S; Ringborg U; Hansson J
Oncol Rep; 2002; 9(5):1015-9. PubMed ID: 12168066
[TBL] [Abstract][Full Text] [Related]
18. Strategies to improve the killing of tumors using temozolomide: targeting the DNA repair protein MGMT.
Jiang G; Li LT; Xin Y; Zhang L; Liu YQ; Zheng JN
Curr Med Chem; 2012; 19(23):3886-92. PubMed ID: 22788764
[TBL] [Abstract][Full Text] [Related]
19. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen.
Taverna P; Liu L; Hanson AJ; Monks A; Gerson SL
Cancer Chemother Pharmacol; 2000; 46(6):507-16. PubMed ID: 11138465
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
Hochhauser D; Glynne-Jones R; Potter V; Grávalos C; Doyle TJ; Pathiraja K; Zhang Q; Zhang L; Sausville EA
Mol Cancer Ther; 2013 May; 12(5):809-18. PubMed ID: 23443801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
